A bone-like composite developed at EPFL uses naturally occurring enzymes to accelerate mineralization through an ...

Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript March 3, 2026 Operator: Hello, and welcome to Nuvation Bio’s Fourth Quarter and Full Year 2020 Financial Results and Corporate Update ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether Alaska Air Group's current ...

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care. In this summary of a panel discussion at the 2026 TTLC ...

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

U.S. Net Product Revenue -- $15.7 million in the fourth quarter and $24.7 million for the full year, with performance ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific ...

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology ...

Orziloben granted Orphan Drug Designation in the U.S. and European UnionCompany expects to report topline results from Phase 2 study in Q3 2026AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V.